Prototypical Stressors

Showing 26 to 50 of 871 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

14	Dibutyl phthalate	1,2-Benzenedicarboxylic acid, dibutyl ester, CAS-RN: 84-74-2, DTXSID2021781	4 AOPs 307: Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring 575: Decreased testosterone synthesis leading to increased nipple retention (NR) in male (rodent) offspring 570: Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring 619: Androgen receptor antagonism leads to delayed preputial separation via reduced fibroblast growth factor in genital-tubercle tissues
521	Bisphenol A	Bisphenol A, CAS-RN: 80-05-7, DTXSID7020182	4 AOPs 314: Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) 522: Estrogen antagonism leading to increased risk of autism-like behavior 535: Binding and activation of GPER leading to learning and memory impairments 554: β-adrenergic receptor agonists leading to arrhythmias.
282	Ketoconazole	Ketoconazole, CAS-RN: 65277-42-1, DTXSID7029879	4 AOPs 218: Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity 219: Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior 349: Inhibition of 11β-hydroxylase leading to decresed population trajectory 606: Ecdysone receptor antagonism leading to mortality via inhibition of chitin synthase 1
191	Clofibrate	Clofibrate, CAS-RN: 637-07-0, DTXSID3020336	3 AOPs 177: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone
776	Sedaxane	Sedaxane, CAS-RN: 874967-67-6, DTXSID2058207	3 AOPs 534: Succinate dehydrogenase (SDH) inhibition leads to oxidative stress 474: Succinate dehydrogenase inactivation leads to cancer by promoting EMT 546: Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms
565	Procymidone	Procymidone, CAS-RN: 32809-16-8, DTXSID9033923	3 AOPs 344: Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring 477: Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring 619: Androgen receptor antagonism leads to delayed preputial separation via reduced fibroblast growth factor in genital-tubercle tissues
202	Fluoxetine		3 AOPs 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 97: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
834	1,1'-Ethane-1,2-diylbis(pentabromobenzene)	1,1'-Ethane-1,2-diylbis(pentabromobenzene), CAS-RN: 84852-53-9, DTXSID2052732	3 AOPs 564: DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. 592: DBDPE-induced DNA strand breaks and LDH activity inhibition leading to population growth rate decline via energy metabolism disrupt and apoptosis 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration
775	Bixafen	Bixafen, CAS-RN: 581809-46-3, DTXSID6058134	3 AOPs 534: Succinate dehydrogenase (SDH) inhibition leads to oxidative stress 474: Succinate dehydrogenase inactivation leads to cancer by promoting EMT 546: Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms
774	Boscalid	Boscalid, CAS-RN: 188425-85-6, DTXSID6034392	3 AOPs 534: Succinate dehydrogenase (SDH) inhibition leads to oxidative stress 474: Succinate dehydrogenase inactivation leads to cancer by promoting EMT 546: Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms
395	Antimycin A	Antimycin A, CAS-RN: 1397-94-0, DTXSID9032325	3 AOPs 286: Mitochondrial complex III antagonism leading to growth inhibition (1) 287: Mitochondrial complex III antagonism leading to growth inhibition (2) 587: Inhibition of the mitochondrial complex III of nigro-striatal neurons leads to parkinsonian motor deficits
224	nanoparticles		3 AOPs 144: Endocytic lysosomal uptake leading to liver fibrosis 392: Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation 451: Interaction with lung resident cell membrane components leads to lung cancer
65	Di(2-ethylhexyl) phthalate	Di(2-ethylhexyl) phthalate, CAS-RN: 117-81-7, DTXSID5020607	3 AOPs 457: Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine 575: Decreased testosterone synthesis leading to increased nipple retention (NR) in male (rodent) offspring 570: Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring
650	Methyl parathion	Methyl parathion, CAS-RN: 298-00-0, DTXSID1020855	3 AOPs 405: Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function 450: Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality 561: Aromatase induction leading to estrogen receptor alpha activation via increased estradiol
172	Tamoxifen	Tamoxifen, CAS-RN: 10540-29-1, DTXSID1034187	3 AOPs 165: Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse 440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation
538	Benzo(a)pyrene	Benzo(a)pyrene, CAS-RN: 50-32-8, DTXSID2020139	3 AOPs 644: Bulky DNA adducts leading to chromosomal aberrations and mutations 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
171	Pyrethrins and Pyrethroids		3 AOPs 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse 442: Binding to voltage gate sodium channels during development leads to cognitive impairment 553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure
46	Phenanthrene	Phenanthrene, CAS-RN: 85-01-8, DTXSID6024254	3 AOPs 644: Bulky DNA adducts leading to chromosomal aberrations and mutations 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
318	Carbon nanotubes		3 AOPs 241: Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis 237: Substance interaction with lung resident cell membrane components leading to atherosclerosis via acute phase response 409: Frustrated phagocytosis leads to malignant mesothelioma
861	Anthracene	Anthracene, CAS-RN: 120-12-7, DTXSID0023878	3 AOPs 644: Bulky DNA adducts leading to chromosomal aberrations and mutations 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
862	Pyrene	Pyrene, CAS-RN: 129-00-0, DTXSID3024289	3 AOPs 644: Bulky DNA adducts leading to chromosomal aberrations and mutations 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
26	Fadrozole	Fadrozole, CAS-RN: 102676-47-1, DTXSID5034141	3 AOPs 153: Aromatase Inhibition leading to Ovulation Inhibition and Decreased Fertility in Female Rats 346: Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation 25: Aromatase inhibition leading to reproductive dysfunction
863	Benz(a)anthracene	Benz(a)anthracene, CAS-RN: 56-55-3, DTXSID5023902	3 AOPs 644: Bulky DNA adducts leading to chromosomal aberrations and mutations 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
526	SARS-CoV		3 AOPs 320: Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 430: Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation
295	serotonin transporter activation		3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation